ライフサイエンスコーパス: osteoprotegerin

1 to that of its physiological decoy receptor osteoprotegerin.

2 ngiogenesis, which was completely blocked by osteoprotegerin.

3 sible using antibodies to RANKL or synthetic osteoprotegerin.

4 ifically blocked by the RANKL decoy receptor osteoprotegerin.

5 decreased expression of RANKL and increased osteoprotegerin.

6 ) that could be blocked by pretreatment with osteoprotegerin.

7 shed expression of the RANKL decoy receptor, osteoprotegerin.

8 P, fibrinogen, sICAM-1, sTNFRI, sTNFRII, and osteoprotegerin.

9 ing factor-1, and decrease the expression of osteoprotegerin.

10 by concurrent treatment with ibandronate or osteoprotegerin.

11 colony-stimulating factor, RANK ligand, and osteoprotegerin.

12 K on osteoclast surfaces by RANKL similar to osteoprotegerin.

13 es, the most pronounced increase was seen in osteoprotegerin.

14 asma levels of osteopontin, osteocalcin, and osteoprotegerin (204%, 148%, and 55%, respectively; P <

15 cation (fibroblast growth factor-23 and OPG [osteoprotegerin]), 3 inflammatory biomarkers (tumor necr

16 epressed osteoclast progenitor expression of osteoprotegerin, a decoy receptor for RANKL previously t

17 EAK- or RANKL-neutralizing antibodies and by osteoprotegerin, a decoy receptor for RANKL.

18 This effect was inhibited by osteoprotegerin, a decoy receptor for receptor activator

19 proteins regulates osteoblast expression of Osteoprotegerin, a major inhibitor of osteoclast differe

20 e of the genes identified in this screen was osteoprotegerin, a member of the tumor necrosis factor r

21 Administration of osteoprotegerin, a naturally secreted decoy receptor tha

22 Here we show that osteoprotegerin, a secreted 'decoy' receptor that inhibi

23 Targeting the RANKL pathway by osteoprotegerin administration abrogated periodontal bon

24 king finding was the significant decrease in osteoprotegerin, an osteoclastogenesis inhibitory factor

25 up EP-HN019 presented greater expressions of osteoprotegerin and beta-defensins than group EP (P <0.0

26 vels of biomarkers of vascular inflammation (osteoprotegerin and C-terminal proendothelin-1, adjusted

27 Deletion of Cnb1 increased expression of osteoprotegerin and decreased expression of RANKL.

28 al fibroblasts, increasing the expression of osteoprotegerin and decreasing receptor activator of nuc

29 Group EP-HD100 presented greater levels of osteoprotegerin and gene expression of interleukin (IL)-

30 Over time, a decrease in osteoprotegerin and interleukin-1beta concentrations in

31 ow that muscle cells can produce and secrete osteoprotegerin and pharmacologic treatment of dystrophi

32 We found that serum levels of osteoprotegerin and soluble osteoclast differentiation f

33 Osteoprotegerin and vWF levels increased in participants

34 ys a unique role in osteocytes, up-regulates osteoprotegerin and Wnt signaling, and differentially re

35 -polymerase chain reaction (RT-PCR) for OPG (osteoprotegerin); and RANKL (receptor activator of NF-ka

36 Some of these, including oxidized lipids, osteoprotegerin, and bisphosphonates, appear to regulate

37 rcarboxylated osteocalcin (%ucOC)] and IL-6, osteoprotegerin, and C-reactive protein (CRP) concentrat

38 Concentrations of IL-6, osteoprotegerin, and CRP and bone mineral density (BMD)

39 ces were observed in the 3-y change in IL-6, osteoprotegerin, and CRP concentrations between particip

40 ion regulators bone morphogenetic protein 2, osteoprotegerin, and interleukin 6.

41 g regulators of vascular calcification (OPN, osteoprotegerin, and leptin), PTH(1-34) regulated only s

42 lis infection, while mRNA for interleukin-1, osteoprotegerin, and STAT6 all increased in the suscepti

43 -H+-ATPase inhibitor SB 242784, the cytokine osteoprotegerin, and the amino bisphosphonates alendrona

44 tivator of nuclear factor-kappaB ligand, and osteoprotegerin; and up-regulate osteoclast formation.

45 Plasma osteoprotegerin, angiopoietin-2, and von Willebrand Fact

46 igand (RANKL) and variable downregulation of osteoprotegerin are implicated, and bone health may impr

47 aB ligand (RANKL) and its receptors RANK and osteoprotegerin are key regulators of bone remodeling bu

48 e investigated whether circulating levels of osteoprotegerin are related to features of CMV disease a

49 ligand RANKL, and the soluble decoy receptor osteoprotegerin are the key regulators of osteoclast dif

50 Our data identify osteoprotegerin as a novel protector of muscle integrity

51 ctivator of NF kappa B ligand and suppresses osteoprotegerin at concentrations two logs lower than th

52 h the receptor activator of NF-kappaB ligand/osteoprotegerin axis was unaffected, expression of tumor

53 of a distinct program of genes that included osteoprotegerin, BCL-2, and IAP-1 (inhibitor of apoptosi

54 Knock-down of the expression of osteoprotegerin, BCL-2, or inhibitor of apoptosis protei

55 pression of osteoblast alkaline phosphatase, osteoprotegerin, collagen, and Runx2.

56 vary biomarkers (especially MMP-8 and -9 and osteoprotegerin) combined with red-complex anaerobic per

57 nuclear factor-kappaB ligand and decrease in osteoprotegerin, compared to WTI mice.

58 The association observed between increased osteoprotegerin concentrations and periodontitis was los

59 Salivary osteoprotegerin concentrations were higher in the GP and

60 A truncate of osteoprotegerin, containing the ligand-binding domains b

61 appaB ligand (RANKL) coupled with decline in osteoprotegerin correlate with decreased bone mineral de

62 However, TNFRSF11B (osteoprotegerin) correlated with NPTP as well as plastic

63 , whereas decoy receptor 1 (DcR1), DcR2, and osteoprotegerin counteract this function.

64 Juvenile Paget's disease can result from osteoprotegerin deficiency caused by homozygous deletion

65 Osteoprotegerin deficiency could explain juvenile Paget'

66 However, a neutralizing antibody to osteoprotegerin did not rescue reduced OCL formation in

67 Suppression of osteoclast formation with osteoprotegerin dose-dependently inhibited angiogenesis

68 nate zoledronic acid and the RANKL inhibitor osteoprotegerin, each blocked GM-CSF-induced tumor growt

69 of the osteoclastogenesis inhibitory factor osteoprotegerin enabled early growth of SS18-SSX2-transf

70 hematical model based on type I collagen and osteoprotegerin expression that predicts the bone-formin

71 aB ligand (RANKL) production, an increase in osteoprotegerin expression, and a decrease in serum tart

72 ANKL and M-CSF, saturating concentrations of osteoprotegerin failed to inhibit approximately 40% of t

73 nic diet-fed ldlr(-/-) mice with recombinant osteoprotegerin (Fc-OPG) or vehicle for 5 months.

74 o-color flow cytometry using FITC-conjugated osteoprotegerin-Fc (OPG-Fc-FITC) as a probe.

75 AT/enhancer-binding protein-beta and -delta, osteoprotegerin, FOXC2 and FOXF2, BMP-2, p75 neurotrophi

76 eceived an injection of anti-RANKL antibody, osteoprotegerin fusion protein (OPG-Fc), or a control fu

77 This effect was antagonized by injection of osteoprotegerin fusion protein into the local gingival t

78 by incubation with the RANKL decoy receptor osteoprotegerin fusion protein.

79 showed that Smad1 activates osteopontin and osteoprotegerin gene expression by dislodging Hoxc-8 fro

80 801, on chromosome 8, near to the TNFRSF11B (osteoprotegerin) gene, and rs3736228, on chromosome 11 i

81 The newly described agent osteoprotegerin has been shown in early studies to inhib

82 blocked by treatment with human recombinant osteoprotegerin (hrOPG).

83 ppa B ligand at day 7 post-treatment, strong osteoprotegerin immunoreactivity was observed at day 15

84 by NF-kappaB and indicate a new function for osteoprotegerin in endothelial cells.

85 shed novel roles for tumor-derived CCL20 and osteoprotegerin in inducing CCL2 production from macroph

86 one marrow fibrosis and stromal cell-derived osteoprotegerin in promoting osteosclerosis.

87 ace membrane fibroblasts expressed RANKL and osteoprotegerin in response to stimulation with conditio

88 These data support a role for osteoprotegerin in the vasculature as an inhibitor of ca

89 The role of osteoprotegerin in vascular disease is unclear.

90 turnover, including interleukin-6 (IL-6) and osteoprotegerin in vitro.

91 conjunction with their shared decoy receptor osteoprotegerin, in the bone marrow of infected IFrag(-/

92 To test whether osteoprotegerin induces or prevents vascular disease, we

93 (3)-mediated endothelial survival depends on osteoprotegerin induction by NF-kappaB and indicate a ne

94 Osteoprotegerin induction by osteopontin was time-depend

95 or in endothelial cells completely inhibited osteoprotegerin induction by osteopontin.

96 Osteoprotegerin is a marker of vascular and systemic inf

97 on SLA and modSLA [e.g., prostaglandin E(2), osteoprotegerin, latent and active TGF-beta1, and stimul

98 osis factor (TNF)-alpha, C-reactive protein, osteoprotegerin, leptin, and adiponectin were determined

99 , a calcium-sensing receptor related factor, osteoprotegerin, leptin, bisphosphonates and oxidized li

100 icipants inoculated with P. vivax, where the osteoprotegerin level correlated with the levels of para

101 Recent observational studies show that serum osteoprotegerin levels are associated with the severity

102 Our finding indicates that elevated osteoprotegerin levels in solid organ transplant recipie

103 essive atherosclerosis with increased plasma osteoprotegerin levels, consistent with observational st

104 Osteoprotegerin Ligand (OPGL) is a member of the tumor n

105 Osteoprotegerin ligand (OPGL) targets osteoclast precurs

106 ivator of NF-kappaB (RANK), the receptor for osteoprotegerin ligand (OPGL), also known as RANK ligand

107 tem is enhanced by the addition of exogenous osteoprotegerin ligand (OPGL), an essential Ocl differen

108 A receptor that mediates osteoprotegerin ligand (OPGL)-induced osteoclast differe

109 insic cell surface determinant that mediates osteoprotegerin ligand effects on bone resorption and re

110 nduced cytokine (TRANCE, also referred to as osteoprotegerin ligand), and kit ligand-1 (KL-1) in vitr

111 enetic interactions between osteoprotegerin, osteoprotegerin ligand, and RANK during bone resorption

112 t differentiation factor (ODF; also known as osteoprotegerin ligand, receptor activator of nuclear fa

113 01 with Bonferroni correction for both), but osteoprotegerin lost significance after age and sex adju

114 differentiation and calcification inhibitors osteoprotegerin, matrix Gla protein, and osteopontin.

115 c and treatment studies in mice suggest that osteoprotegerin may protect against vascular calcificati

116 the generation of bone cancer pain and that osteoprotegerin may provide an effective treatment for t

117 of soluble RANKL, but not its decoy receptor osteoprotegerin, measured in diseased tissue homogenates

118 ding macrophage inflammatory protein-1Delta, osteoprotegerin, monokine induced by interferon-gamma (I

119 In contrast, osteoprotegerin mRNA and protein levels were induced 5-7

120 By Northern and Western blot analysis, osteoprotegerin mRNA and protein levels were very low in

121 ndent osteoclastic activity due to decreased osteoprotegerin mRNA expression in these cells.

122 3, macrophage colony-stimulating factor, and osteoprotegerin mRNA expression.

123 Inhibition of osteoprotegerin mRNA in WT cells was partial with either

124 Vit D decreased osteoprotegerin mRNA to undetectable in all groups.

125 Osteoprotegerin mRNA was increased, sclerostin and dickk

126 hosphatase mRNA levels, and potently induced osteoprotegerin mRNA, whereas LiCl was ineffective alone

127 tin but decreased expression of osteocalcin, osteoprotegerin (mRNA and protein), and smad2.

128 Tumor necrosis factor and osteoprotegerin mRNAs are more highly expressed in the g

129 ment of dystrophic mdx mice with recombinant osteoprotegerin muscles.

130 TNF-related apoptosis-inducing ligand; OPG, osteoprotegerin; Omp29, 29-kDa outer membrane protein; P

131 r of nuclear factor kappaBeta ligand (RANKL)/osteoprotegerin (OPG) (2.5 +/- 0.7-fold, p < 0.001) rati

132 Both osteoprotegerin (OPG) and anti-TNF antibodies inhibited

133 ons on structurally conserved ectodomains of osteoprotegerin (OPG) and decoy receptor 3, other two se

134 Osteoprotegerin (OPG) and receptor activator of nuclear

135 KL) mRNA, whereas ES increased expression of osteoprotegerin (OPG) and the OPG/RANKL ratio.

136 o compare the activity of TSG-6 with that of osteoprotegerin (OPG) and to investigate its role as an

137 r activator of NF-kappaB) and decoy receptor osteoprotegerin (OPG) are constitutively expressed at al

138 uclear factor-kappabeta ligand (sRANKL), and osteoprotegerin (OPG) at baseline (the date of initiatio

139 tor for NF-kappaB (RANK)/RANK ligand (RANKL)/osteoprotegerin (OPG) axis and expression of the transcr

140 ar factor-kappa B (RANK)-RANK ligand (RANKL)-osteoprotegerin (OPG) axis.

141 L-6) in iDCs and also increased secretion of osteoprotegerin (OPG) by DCs.

142 nic markers, alkaline phosphatase (ALP), and osteoprotegerin (OPG) by hMSCs and transcriptome analysi

143 ulatory factors in osteoblasts by decreasing osteoprotegerin (OPG) expression and increasing monocyte

144 ld lower RANKL expression but >2-fold higher osteoprotegerin (OPG) expression than donor-matched ABCs

145 ormone-related protein (PTHrP) down-regulate osteoprotegerin (OPG) gene expression in the dental foll

146 of nuclear factor kappa B ligand (RANKL) and osteoprotegerin (OPG) immunohistochemistry was carried o

147 All treatments upregulated mRNA levels for osteoprotegerin (OPG) in comparison to PLAC (P < 0.05).

148 IL-6, IL-8, tumor necrosis factor-alpha, and osteoprotegerin (OPG) in HGF and HPLF.

149 High systemic levels of osteoprotegerin (OPG) in OPG transgenic mice cause osteo

150 from tumor cells suppress the expression of osteoprotegerin (OPG) in osteoblasts and subsequently po

151 s and indirectly by increasing expression of osteoprotegerin (Opg) in osteoblasts.

152 bular molar, a decrease in the expression of osteoprotegerin (OPG) in the dental follicle at day 3 en

153 ukin (IL)-17A, IL-17E, IL-17F, IL-17A/F, and osteoprotegerin (OPG) in women with rheumatoid arthritis

154 lear factor-kappa B ligand (RANKL) inhibitor osteoprotegerin (OPG) inhibits osteoclastogenesis and su

155 Osteoprotegerin (OPG) inhibits RANK signaling by sequest

156 ator of Nfkb ligand (RANKL) activates, while osteoprotegerin (OPG) inhibits, osteoclastogenesis.

157 The secreted, soluble receptor osteoprotegerin (OPG) interrupts this activation by bind

158 Osteoprotegerin (OPG) is a CD40-regulated gene in B cell

159 Osteoprotegerin (OPG) is a decoy receptor for tumor necr

160 Osteoprotegerin (OPG) is a glycoprotein that acts as a d

161 Osteoprotegerin (OPG) is a key regulator of bone remodel

162 Osteoprotegerin (OPG) is a marker and regulator of arter

163 Osteoprotegerin (OPG) is a member of the tumor necrosis

164 Osteoprotegerin (OPG) is a soluble nonsignaling receptor

165 Osteoprotegerin (OPG) is an osteoblast-secreted glycopro

166 The secreted glycoprotein osteoprotegerin (OPG) is emerging as an important regula

167 Osteoprotegerin (OPG) is increased within serum and lesi

168 Osteoprotegerin (OPG) is involved in bone homeostasis an

169 of nuclear factor-kappaB ligand (RANKL) and osteoprotegerin (OPG) levels and RANKL/OPG ratios in ser

170 pressed significantly higher RANKL and lower osteoprotegerin (OPG) mRNA and increased RANKL:OPG ratio

171 uclear factor kappaB ligand (RANKL) and RANK/osteoprotegerin (OPG) plays a dominant role in osteoclas

172 of nuclear factor kappaB ligand (RANKL) with osteoprotegerin (OPG) prevents the osteolytic activity o

173 or activator of NF-kappaB ligand (RANKL) and osteoprotegerin (OPG) production by ST2 cells, despite M

174 igand (RANKL) expression and down-regulating osteoprotegerin (OPG) production.

175 f nuclear factor kappaB ligand) promotes and osteoprotegerin (OPG) protects against vascular calcific

176 ce with established myeloma with recombinant osteoprotegerin (OPG) protein, the soluble decoy recepto

177 e dermatomyositis (DM), to compare the RANKL:osteoprotegerin (OPG) ratio in patients with juvenile DM

178 f nuclear factor kappa-B ligand (RANKL)-RANK-osteoprotegerin (OPG) signaling associated with bone res

179 or activator of NF-kappaB ligand (RANKL) and osteoprotegerin (OPG) signaling in osteocytes was not st

180 ctor-kappaB (RANK), RANK ligand (RANKL), and osteoprotegerin (OPG) signaling pathway (RANKL/RANK/OPG

181 r activator of NF-kappaB ligand (RANKL), and osteoprotegerin (OPG) that modulate bone homeostasis.

182 ivator of nuclear factor kappa-B (RANKL) and osteoprotegerin (OPG) to diagnose healthy peri-implant c

183 We found that the expression of osteoprotegerin (OPG) was induced by genistein and inhib

184 The gene for osteoprotegerin (OPG) was up-regulated by both parasites

185 ctor kappaB (RANK), RANK ligand (RANKL), and osteoprotegerin (OPG) were also investigated by immunohi

186 tion of RANKL and its competitive antagonist osteoprotegerin (OPG) were analyzed by ELISA, quantitati

187 of nuclear factor-kappaB ligand (RANKL), and osteoprotegerin (OPG) were analyzed in the furcation are

188 of nuclear factor-kappaB ligand (RANKL) and osteoprotegerin (OPG) were assessed by enzyme-linked imm

189 of nuclear factor kappaB ligand (RANKL), and osteoprotegerin (OPG) were determined by immunohistochem

190 tor of nuclear factor-kappa B (RANKL) and of osteoprotegerin (OPG) were evaluated by immunofluorescen

191 or kappa B ligand (RANKL) and its antagonist osteoprotegerin (OPG) were measured prospectively before

192 onocyte chemoattractant protein (MCP)-1, and osteoprotegerin (OPG) were measured with qPCR and ELISA.

193 s, RvE1 significantly enhanced expression of osteoprotegerin (OPG) without inducing change in recepto

194 Osteoprotegerin (OPG), a critical regulator of osteoclas

195 Serum levels of osteoprotegerin (OPG), a decoy receptor for RANKL, stead

196 teoclastogenesis by inhibiting expression of osteoprotegerin (OPG), a decoy receptor for the receptor

197 Osteoprotegerin (OPG), a decoy receptor secreted by oste

198 Osteoprotegerin (OPG), a member of the tumor necrosis fa

199 Osteoprotegerin (OPG), a natural negative regulator of o

200 Osteoprotegerin (OPG), a novel, secreted tumor necrosis

201 or of nuclear factor-kappaB ligand (sRANKL), osteoprotegerin (OPG), a proliferation-inducing ligand (

202 t survival, in part through the induction of osteoprotegerin (OPG), a protein known to inhibit osteoc

203 Osteoprotegerin (OPG), a secreted decoy receptor for rec

204 hormones or cytokines, and is neutralized by osteoprotegerin (OPG), a soluble decoy receptor also cru

205 addition to its effects on bone metabolism, osteoprotegerin (OPG), a soluble member of the tumor nec

206 Osteoprotegerin (OPG), a soluble receptor of the cytokin

207 Osteoprotegerin (OPG), an immunoregulatory member of the

208 nd activation, we examined the expression of osteoprotegerin (OPG), an inhibitor of osteoclast format

209 imulated expression of interleukin-6 but not osteoprotegerin (OPG), an inhibitor of RANKL.

210 Osteoprotegerin (OPG), an osteoblast-secreted decoy rece

211 Interleukin (IL)-1beta, osteoprotegerin (OPG), and bone-specific alkaline phosph

212 ptor activator of NF-kappa B ligand (RANKL), osteoprotegerin (OPG), and monocyte chemotactic and stim

213 r factor-kappaB (RANK), RANK-ligand (RANKL), osteoprotegerin (OPG), and osteocalcin was performed.

214 he levels and relative ratios of sclerostin, osteoprotegerin (OPG), and receptor activator of nuclear

215 or of nuclear factor-kappa B ligand (RANKL), osteoprotegerin (OPG), and tartrate-resistant acid phosp

216 tor of nuclear factor kappaB ligand (RANKL), osteoprotegerin (OPG), and tartrate-resistant acid phosp

217 ctivator of nuclear factor-kappaB (RANK) and osteoprotegerin (OPG), are known to be regulators of dev

218 r of nuclear factor-kappa B ligand (sRANKL), osteoprotegerin (OPG), B-cell activating factor (BAFF),

219 oclast numbers and activity are regulated by osteoprotegerin (OPG), bisphosphonates suppress osteocla

220 kappaB (RANK), soluble RANK ligand (sRANKL), osteoprotegerin (OPG), cathepsin-K, and sclerostin.

221 on index (ACI), fibroblast growth factor 23, osteoprotegerin (OPG), fetuin A, and clinical and bioche

222 of TRAIL, DR5 and the TRAIL decoy receptors osteoprotegerin (OPG), mDcTRAILR1, and mDcTRAILR2 were d

223 gate virus, we found that a soluble protein, osteoprotegerin (OPG), or an OPG/Fc chimeric protein inh

224 of Nuclear factor Kappa B Ligand (RANKL) and osteoprotegerin (OPG), positive and negative regulators

225 Osteoprotegerin (OPG), receptor activator of nuclear fac

226 d soluble TNF receptor type I (pegTNFRI) and osteoprotegerin (OPG), respectively, affected bony spur

227 tor of nuclear factor-kappaB ligand (RANKL), osteoprotegerin (OPG), tartrate-resistant acid phosphata

228 nce with RANKL by systemic administration of osteoprotegerin (OPG), the decoy receptor for (and inhib

229 ceptor activator of NF-kappaB ligand (RANKL)/osteoprotegerin (OPG), tumor necrosis factor alpha (TNF-

230 tor of nuclear factor-kappaB ligand (RANKL), osteoprotegerin (OPG), wingless (WNT) 10b, dickkopf-rela

231 recent work showed that daily injections of osteoprotegerin (OPG)-immunoglobulin fragment complex (O

232 predictive markers of bone inflammation-the osteoprotegerin (OPG)-RANK-RANKL system or osteopontin (

233 ng increased expression of RANKL, M-CSF, and osteoprotegerin (OPG).

234 gand (RANKL) relative to its decoy receptor, osteoprotegerin (OPG).

235 nuclear factor-kappaBeta ligand (RANKL) and osteoprotegerin (OPG).

236 inhibited by a soluble decoy receptor called osteoprotegerin (OPG).

237 ctor-kappaB, and subsequent up-regulation of osteoprotegerin (OPG).

238 and (RANKL) and inhibiting the expression of osteoprotegerin (OPG).

239 (TRANCE) and decrease in its decoy receptor, osteoprotegerin (OPG).

240 inistration of the decoy receptor for RANKL, osteoprotegerin (OPG).

241 cross-talk through the direct regulation of osteoprotegerin (OPG).

242 factor-kappaB ligand and decreased levels of osteoprotegerin (OPG).

243 stogenesis due to insufficient production of osteoprotegerin (Opg).

244 Elevated ratio of osteoprotegerin (OPG)/receptor activator of nuclear fact

245 of nuclear factor-kappa B ligand (RANKL); 2) osteoprotegerin (OPG); 3) interleukin (IL)-6; and 4) tum

246 eine chemokine receptor-5 (CCR5, 59653 C>T), osteoprotegerin (OPG, 245 T>G), and osteopontin (OPN, 70

247 osteopontin [OPN], bone sialoprotein [BSP], osteoprotegerin [OPG] and receptor activator of NF-KB li

248 mentation rate, and bone metabolism markers (osteoprotegerin [OPG], osteocalcin, procollagen type I N

249 hymic epithelial cells by using mice lacking osteoprotegerin or by adding TRANCE (RANKL, Tnfsf11).

250 this system with recombinant decoy receptor, osteoprotegerin, or soluble forms of the receptor activa

251 r for nuclear factor kappa-B ligand (RANKL), osteoprotegerin, osteocalcin, and osteopontin as potenti

252 Salivary levels of RANKL, osteoprotegerin, osteocalcin, osteopontin, and serum gly

253 steoblast markers bone alkaline phosphatase, osteoprotegerin, osteopontin, and matrix Gla protein.

254 e the molecular genetic interactions between osteoprotegerin, osteoprotegerin ligand, and RANK during

255 Targeting the RANKL/osteoprotegerin pathway may lead to therapies that impro

256 although EDNRA activation had no effects on osteoprotegerin production.

257 Finally, purified osteoprotegerin protected endothelial cells with inactiv

258 After 6 days of treatment, osteoprotegerin protein in cell supernatants was 40-fold

259 whereas no inhibition was observed by adding osteoprotegerin, RANK:Fc, TNFalpha, or interleukin-8 or

260 high receptor activator of NF-kappaB ligand/osteoprotegerin (RANKL/OPG) ratio as the primary determi

261 This is achieved by decreasing the osteoprotegerin/RANKL expression ratio.

262 ppaB ligand (RANKL)), the deviation of RANKL/osteoprotegerin ratio in favor of antiosteoclastic activ

263 duced receptor activator of NF-kappaB ligand/osteoprotegerin ratio in Runx2-overexpressing osteoblast

264 kin-6, interleukin-1beta, bone sialoprotein, osteoprotegerin, receptor activator of nuclear factor ka

265 l analyses for the detection of osteocalcin, osteoprotegerin, receptor activator of nuclear factor ka

266 on-gamma, toll-like receptor (TLR)-2, TLR-4, osteoprotegerin, receptor activator of nuclear factor-ka

267 pha1, osteocalcin, alkaline phosphatase, and osteoprotegerin, representative bone-regulating proteins

268 osteoblast differentiation, also stimulates osteoprotegerin secretion to attenuate bone resorption b

269 A substantial part of the actions of osteoprotegerin seems to result from inhibition of tumor

270 This enhanced chemotaxis can be abrogated by osteoprotegerin (soluble decoy receptor of RANKL), MIK-G

271 The more pronounced increase in osteoprotegerin suggests that this biomarker may play a

272 uld explain juvenile Paget's disease because osteoprotegerin suppresses bone turnover by functioning

273 The map locations of 25 genes including osteoprotegerin, syndecan-2, and autotaxin have been ref

274 receptor activator of nuclear factor kappa B/osteoprotegerin system involved in osteoblast-osteoclast

275 Manipulation of the RANKL/osteoprotegerin system now is feasible using antibodies

276 ew, we provide an overview of the RANK/RANKL/osteoprotegerin system; we describe its interaction with

277 g proteins, like hepatocyte growth factor or osteoprotegerin, they concentrate in the uropod.

278 f receptor activator of NF-kappaB ligand and osteoprotegerin through both PTH-dependent and -independ

279 t's disease for defects in the gene encoding osteoprotegerin (TNFRSF11B) using polymerase-chain-react

280 rationally designed small molecule mimic of osteoprotegerin to inhibit osteoclast formation in vitro

281 lance stemmed from a switch in production of osteoprotegerin to that of receptor activator of NF-kapp

282 However, OC-defective osteoprotegerin transgenic (OPG(Tg)) mice and bisphospho

283 Results indicated that osteoprotegerin treatment halted further bone destructio

284 Gene expression levels of soluble RANKL, osteoprotegerin, tumor necrosis factor alpha, and M-CSF

285 ator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin, tumor necrosis factor-alpha, and interl

286 eptor-activated nuclear factor-kappaB ligand/osteoprotegerin/tumor necrosis factor-related apoptosis-

287 Osteoprotegerin was associated positively with plasma ph

288 Elevated plasma osteoprotegerin was associated with (i) certain disease

289 sitive to the effects of the RANKL inhibitor osteoprotegerin was identified in the activated T cell-c

290 steocalcin, and osteopontin were higher, and osteoprotegerin was lower in females than in males.

291 ctivator of nuclear factor-kappaB ligand and osteoprotegerin) was observed in the ligature group on d

292 Alterations in BM plasma levels of RANKL/osteoprotegerin were confirmed in a mouse model of posti

293 F-kappaB ligand (RANKL), and its antagonist, osteoprotegerin were measured.

294 scular cell adhesion molecule 1 (VCAM-1) and osteoprotegerin were significantly associated with incid

295 lasma levels of RANKL and of the ratio RANKL/osteoprotegerin were significantly elevated in patients

296 d macrophage inflammatory protein-1Delta and osteoprotegerin were significantly elevated in patients

297 Osteopontin and osteoprotegerin were significantly elevated in the sympt

298 hereas other genes, such as interleukin-5 or osteoprotegerin, were initially identified as having a r

299 or Tax and the osteoclast inhibitory factor, osteoprotegerin, were protected from osteolytic bone dis

300 Osteoprotegerin, which was expressed constitutively, was